Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications. It is taken by mouth.
The analysis highlights History, Applications and Research as prominent areas in the source structure around Cabergoline.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
The extracted context around Cabergoline shows recurring relationship patterns in the source. For example, Cabergoline → Although, D1, D2, D3, D4, Ergot, HT1A, HT2A, HT2B, HT2C, HT7, In-vitro Another extracted example is Cabergoline → Additionally, Also, GDNF, It, IVF, OHSS, One, Oral, SSRI, Vaginal. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
effects side disease treatment patients pregnancy hyperprolactinemia used ergot also parkinson's use may lactation dostinex derivatives dopamine agonist frequent drug
TTTA extracted 123 structured relationships around Cabergoline. Examples in this analysis include Cabergoline → 3D model (JSmol) → Interactive image and Cabergoline → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Cabergoline | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Cabergoline | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Cabergoline | ATC code | G02CB03 (WHO) N04BC06 (WHO) | 1.00 | infobox |
| Cabergoline | Bioavailability | 50–80% | 1.00 | infobox |
| Cabergoline | CAS Number | 81409-90-7 Y | 1.00 | infobox |
| Cabergoline | ChEBI | CHEBI:3286 Y | 1.00 | infobox |
| Cabergoline | ChEMBL | ChEMBL1201087 N | 1.00 | infobox |
| Cabergoline | ChemSpider | 49452 Y | 1.00 | infobox |
| Cabergoline | CompTox Dashboard (EPA) | DTXSID6022719 | 1.00 | infobox |
| Cabergoline | DrugBank | DB00248 Y | 1.00 | infobox |
| Cabergoline | ECHA InfoCard | 100.155.380 | 1.00 | infobox |
| Cabergoline | Elimination half-life | 63–69 hours (estimated) | 1.00 | infobox |
| Cabergoline | Excretion | Urine (22%), feces (60%) | 1.00 | infobox |
| Cabergoline | Formula | C26H37N5O2 | 1.00 | infobox |
| Cabergoline | IUPHAR/BPS | 37 | 1.00 | infobox |
| Cabergoline | KEGG | D00987 Y | 1.00 | infobox |
| Cabergoline | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Cabergoline | Legal status | US: ℞-only | 1.00 | infobox |
| Cabergoline | License data | US DailyMed: Cabergoline | 1.00 | infobox |
| Cabergoline | Metabolism | Liver, predominately via hydrolysis of the acylurea bond or the urea moiety | 1.00 | infobox |
| Cabergoline | Molar mass | 451.615 g·mol−1 | 1.00 | infobox |
| Cabergoline | Other names | N-[3-(Dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8β-carboxamide | 1.00 | infobox |
| Cabergoline | Protein binding | Moderately bound (40–42%); concentration-independent | 1.00 | infobox |
| Cabergoline | PubChem CID | 54746 | 1.00 | infobox |
| Cabergoline | Routes of administration | Oral | 1.00 | infobox |
| Cabergoline | Trade names | Dostinex, others | 1.00 | infobox |
| Cabergoline | UNII | LL60K9J05T | 1.00 | infobox |
| Cabergoline | is a | ergot derivative and a potent dopamine D2 receptor agonist.Cabergoline was patented in 1980 and approved for medical use in 1993 | 0.90 | text |
The concept neighborhoods around Cabergoline bring nearby vocabulary together. In this analysis, examples include Disease, Treatment and Effects. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Cabergoline, one of the stronger structural bridges in this analysis connects Cabergoline with Side effects. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Cabergoline to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Applications & Research, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Cabergoline · EN edition · Analysis: TopicsToTalkAbout